Sarepta Therapeutics Inc. (SRPT)

91.65
NASDAQ : Health Technology
Prev Close 89.99
Day Low/High 90.15 / 92.05
52 Wk Low/High 28.82 / 95.67
Avg Volume 1.32M
Exchange NASDAQ
Shares Outstanding 65.53M
Market Cap 5.90B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sarepta And Invitae Expand Partnership To Advance Clinical Research In Duchenne Muscular Dystrophy

--The program helps clinicians identify patients who may be eligible for Sarepta's clinical trials--

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

Rotational action is the main theme Wednesday and good opportunities are out there.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Sarepta Therapeutics Announces Launch Of Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics Announces Launch Of Route 79, The Duchenne Scholarship Program

-- The Company will award 10 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --

Big Cap Tech Was the Play of the Day

Big Cap Tech Was the Play of the Day

With few catalysts for the markets, Tuesday's special election for a Pennsylvania congressional seat could set the tone this week.

There's Plenty of Positive Action But It's a Little Overheated

There's Plenty of Positive Action But It's a Little Overheated

I'll be watching for entry points to develop this afternoon.

There's No Big Rush for the Indices at this Point

There's No Big Rush for the Indices at this Point

The best way to deal with the struggling market is selective stock picking and good defense.

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

With an Eye on Biotech, Here's Today's Trading Thesis

With an Eye on Biotech, Here's Today's Trading Thesis

It is important to note that watching for a reversal is much different than being short.

Focused on Two Sectors

Focused on Two Sectors

If we have a little consolidating action here the buyers will start pushing again.

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.

First Duchenne Muscular Dystrophy Patient Dosed In Systemic Microdystrophin Gene Therapy

First Duchenne Muscular Dystrophy Patient Dosed In Systemic Microdystrophin Gene Therapy

Duchenne Organizations Led by Parent Project Muscular Dystrophy Help Fund Next Step in Cutting-Edge Treatment

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

You Can't Reason With a Steamroller

You Can't Reason With a Steamroller

The momentum is crushing everything in its way.

Selling Action Is Upon Us

Selling Action Is Upon Us

There is still a very strong appetite for individual stocks with momentum.

Stock Indexes Manage Another Day of Gains

Stock Indexes Manage Another Day of Gains

If you're not nervous, you're not paying attention.

TheStreet Quant Rating: D (Sell)